The rearrangement route to 3-carboxy- and 3-hydroxymethyl-2-azabicyclo[2.1. 1]hexanes: 3,5-Methanoprolines

Journal of Organic Chemistry

Volumn 70, Issue 2, 2005, Pages 590-595

  Krow, Grant R ^a   Lin, Guoliang ^a   Yu, Fang ^a  

^a Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITION REACTIONS; STEREOCHEMISTRY; SYNTHESIS (CHEMICAL);

3,5-METHANOPROLINES; PRECURSORS; PYRIDINE; STEREOCONTROLLED SYNTHESIS;

PARAFFINS;

2 PHENYL 1,2 DIHYDROPYRIDINE; 3 CARBOXYMETHYL 2 AZABICYCLO[2.1.1]HEXANE; 3 HYDROXYMETHYL 2 AZABICYCLO[2.1.1]HEXANE; 3,5 METHANOPROLINE; BICYCLO COMPOUND; N (BENZYLOXYCARBONYL) 5 ANTI ACETOXY 3 EXO PHENYL 2 AZABICYCLO[2.1.1]HEXANE; N (BENZYLOXYCARBONYL) 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO METHOXYCARBONYL 2 AZABICYCLO[2.1.1]HEXANE; N (BENZYLOXYCARBONYL)5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO PHENYL 2 AZABICYCLO[2.1.1]HEXANE; N [(CARBOMETHOXYMETHYL)METHOXYCARBONYL] 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO PHENYL 2 AZABICYCLO[2.1.1]HEXANE; N ACETYL 5 ANTI ACETOXY 3 EXO METHOXYCARBONYL 2 AZABICYCLO[2.1.1]HEXANE; N ACETYL 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO (METHOXYCARBONYL) 2 AZABICYCLO[2.1.1]HEXANE; N BENZYLOXYCARBONYL 2 AMINO 5 METHYL 2 CYCLOPENTENONE; N BENZYLOXYCARBONYL 3 (PHENYLDIMETHYLSILYLMETHYL) 2 AZABICYCLO[2.2.0]HEX 5 ENE; N BENZYLOXYCARBONYL 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO (HYDROXYMETHYL) 2 AZABICYCLO[2.1.1]HEXANE; N BENZYLOXYCARBONYL 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO (METHOXYCARBONYL) 2 AZABICYCLO[2.1.1]HEXANE; N BENZYLOXYCARBONYL 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO (PHENYLDIMETHYLSILYLMETHYL) 2 AZABICYCLO[2.1.1]HEXANE; N H 5 ANTI BROMO 6 ANTI ACETOXY 3 ENDO (METHOXYCARBONYL) 2 AZABICYCLO[2.1.1]HEXANE; PROLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADDITION REACTION; ARTICLE; DEBROMINATION; ENANTIOMER; OXIDATION; REACTION ANALYSIS; STEREOCHEMISTRY; SUBSTITUTION REACTION; SYNTHESIS;

EID: 12344283549     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo0484171     Document Type: Article

References (57)

1. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
2. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
3. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
4. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
5. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
6. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
7. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
8. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
9. For leading references with bridged pyrrolidines, see: (a) Bunch, L.; Liljefors, T.; Greenwood, J. R.; Frydenvang, K.; Brauner-Osborne, H.; Krogsgaard-Larsen, P.; Madsen U. J. Org. Chem. 2003, 68, 1489. (b) Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050. (c) Piotroski, D. W. Synlett 1999, 1091. (d) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson, C. M.; Bridges, R. J. Bioorg. Med. Chem. Lett. 1988, 8, 3101. (e) Koch, H. P.; Kavanaugh, M. P.; Esslinger, C. S.; Zerangue, N.; Humphrey, J. M.; Amara, S. G.; Chamberlain, A. R.; Bridges, R. J. Mol. Pharmacol. 1999, 56, 1095. (f) Mapelli, C.; van Halbeek, H.; Stammer, C. H. Biopolymers 1990, 29, 407. (g) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Janzen, D. H.; Lemke, P.; Clardy, J. J. Am. Chem. Soc. 1980, 102, 1409. (h) Han, W.; Pelletier, J. C.; Mersinger, L.; Ketner, C. A.; Hodge, C. N. Org. Lett. 1999, 1, 1875. (i) Park, T. H.; Ha, Y. H.; Jeong, D. Y. Patent Application WO 98-KR246 19989898; Chem. Abstr. 1999, 130, 182388.
10. For a review of naturally occurring proline analogues, see: Mauger, A. B. J. Nat. Prod. 1996, 59, 1205.
11. For a review of 4-hydroxy-L-proline as a building block, see: Remuzon, P. Tetrahedron 1996, 52, 13803.
12. For generation of nonproteinogenic amino acids from 4-hydroxyproline, see: (a) Cheng, W.-C.; Liu, Y.; Wong, M.; Olmstead, M. M.; Lam, K. S.; Kurth, M. J. J. Org. Chem. 2002, 67, 5673. (b) Webb, T. R.; Eigenbrot, C. J. Org. Chem. 1991, 56, 3009. (c) Tamaki, M.; Han, G.; Hruby, V. J. J. Org. Chem. 2001, 66, 1038.
13. For generation of nonproteinogenic amino acids from 4-hydroxyproline, see: (a) Cheng, W.-C.; Liu, Y.; Wong, M.; Olmstead, M. M.; Lam, K. S.; Kurth, M. J. J. Org. Chem. 2002, 67, 5673. (b) Webb, T. R.; Eigenbrot, C. J. Org. Chem. 1991, 56, 3009. (c) Tamaki, M.; Han, G.; Hruby, V. J. J. Org. Chem. 2001, 66, 1038.
14. For generation of nonproteinogenic amino acids from 4-hydroxyproline, see: (a) Cheng, W.-C.; Liu, Y.; Wong, M.; Olmstead, M. M.; Lam, K. S.; Kurth, M. J. J. Org. Chem. 2002, 67, 5673. (b) Webb, T. R.; Eigenbrot, C. J. Org. Chem. 1991, 56, 3009. (c) Tamaki, M.; Han, G.; Hruby, V. J. J. Org. Chem. 2001, 66, 1038.
15. For aminonucleotides based on 4-hydroxyprolinol, see: (a) Reed, M. W.; Lukhtanov, E. A.; Gorn, V. V.; Lucas, D. D.; Zhou, J. H.; Pai, S. B.; Cheng, Y.; Meyer, R. B., Jr. J. Med. Chem. 1995, 38, 4587. (b) Peterson, M. L.; Vince, R. J. Med. Chem. 1991, 34, 2787.
16. For aminonucleotides based on 4-hydroxyprolinol, see: (a) Reed, M. W.; Lukhtanov, E. A.; Gorn, V. V.; Lucas, D. D.; Zhou, J. H.; Pai, S. B.; Cheng, Y.; Meyer, R. B., Jr. J. Med. Chem. 1995, 38, 4587. (b) Peterson, M. L.; Vince, R. J. Med. Chem. 1991, 34, 2787.
17. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
18. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
19. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
20. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
21. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
22. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
23. For peptide nucleic acids from 4-hydroxyproline, see: (a) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 547. (b) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 555. (c) Westwood, N. B.; Walker, R. T. Tetrahedron 1998, 54, 13391. (d) Lowe, G.; Vilaivan, T. J. Chem. Soc., Perkin Trans. 1 1997, 539. (e) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Schwenner, E.; Stropp, U.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 681. (f) Jordan, S.; Schwemler, C.; Kosch, W.; Kretschmer, A.; Stropp, U.; Schwenner, E.; Mielke, B. Bioorg. Med. Chem. Lett. 1997, 7, 687. (g) Puschl, A.; Tedeschi, T.; Nielsen, P. E. Org. Lett. 2000, 2, 4161.
24. For azasugars from 4-hydroxyprolinal, see: Zhu, Y.-H.; Vogel, P. J. Org. Chem. 1999, 64, 666.
25. For incorporation of 4-hydroxyproline derivatives into antibiotics, see: (a) Kamal, A. J. Org. Chem. 1991, 56, 2237. (b) Kamal, A.; Reddy, G. S. K.; Reffy, K. L.; Raghavan, S. Tetrahedron Lett. 2002, 43, 2103. (c) Azami, H.; Barrett, D.; Tanaka, A.; Sasaki, H.; Matsuda, K.; Chiba, T.; Matsumoto, Y.; Matsumoto, S.; Moringa, C.; Ishiguro, K.; Tawara, S.; Sakane, K.; Takasugi, H. Bioorg. Med. Chem. Lett. 1995, 5, 2199.
26. For incorporation of 4-hydroxyproline derivatives into antibiotics, see: (a) Kamal, A. J. Org. Chem. 1991, 56, 2237. (b) Kamal, A.; Reddy, G. S. K.; Reffy, K. L.; Raghavan, S. Tetrahedron Lett. 2002, 43, 2103. (c) Azami, H.; Barrett, D.; Tanaka, A.; Sasaki, H.; Matsuda, K.; Chiba, T.; Matsumoto, Y.; Matsumoto, S.; Moringa, C.; Ishiguro, K.; Tawara, S.; Sakane, K.; Takasugi, H. Bioorg. Med. Chem. Lett. 1995, 5, 2199.
27. For incorporation of 4-hydroxyproline derivatives into antibiotics, see: (a) Kamal, A. J. Org. Chem. 1991, 56, 2237. (b) Kamal, A.; Reddy, G. S. K.; Reffy, K. L.; Raghavan, S. Tetrahedron Lett. 2002, 43, 2103. (c) Azami, H.; Barrett, D.; Tanaka, A.; Sasaki, H.; Matsuda, K.; Chiba, T.; Matsumoto, Y.; Matsumoto, S.; Moringa, C.; Ishiguro, K.; Tawara, S.; Sakane, K.; Takasugi, H. Bioorg. Med. Chem. Lett. 1995, 5, 2199.
28. For use of 4-hydroxyproline in the synthesis of antihypertensives, see: Rrapcho, J.; Turk, C.; Cushman, D. W.; Powell, J. R.; DeForrest, J. M.; Spitzmiller, E. R.; Karanewsky, D. S.; Duggan, M.; Rovnyak, G.; Schwartz, J.; Natarajan, S.; Godfrey, J. D.; Ryono, D. E.; Neubeck, R.; Atwal, K. S.; Petrillo, E. W., Jr. J. Med. Chem. 1988, 31, 1148.
29. For generation of polyamines from 4-hydroxyproline, see: Nagamani, D.; Ganesh, K. N. Org. Lett. 2001, 3, 103.
30. For incorporation of 4-hydroxyproline derivatives into macrocycles, see: (a) Arasappan, A.; Chen, K. X.; Njoroge, F. G.; Parekh, T. N.; Girijavallabhan, V. J. Org. Chem. 2002, 67, 3923. (b) Goldberg, M.; Smith, L., II; Tamayo, N.; Kiselyov, A. S. Tetrahedron 1999, 55, 13887.
31. For incorporation of 4-hydroxyproline derivatives into macrocycles, see: (a) Arasappan, A.; Chen, K. X.; Njoroge, F. G.; Parekh, T. N.; Girijavallabhan, V. J. Org. Chem. 2002, 67, 3923. (b) Goldberg, M.; Smith, L., II; Tamayo, N.; Kiselyov, A. S. Tetrahedron 1999, 55, 13887.
32. For recent synthetic efforts related to the synthesis of 4-substituted-prolines and 2-hydroxymethylpyrrolidines, see: (a) Del Valle, J. R.; Goodman, M. J. Org. Chem. 2003, 68, 3923. (b) Tamaki, M.; Han, G.; Hruby, V. J. J. Org. Chem. 2001, 66, 3593.
33. For recent synthetic efforts related to the synthesis of 4-substituted-prolines and 2-hydroxymethylpyrrolidines, see: (a) Del Valle, J. R.; Goodman, M. J. Org. Chem. 2003, 68, 3923. (b) Tamaki, M.; Han, G.; Hruby, V. J. J. Org. Chem. 2001, 66, 3593.
34. Moore, R. E.; Entzeroth, M. Phytochemistry 1988, 27, 3101.
35. Koehn, F. E.; Longley, R. E.; Reed, J. K. J. Nat. Prod. 1992, 55, 613.
36. (a) Koehn, F. E.; McConnell, O. J.; Longley, R. E.; Sennett, S. H.; Reed, J. K. J. Med. Chem. 1994, 37, 3181.
37. (b) Dicicco, C. P.; Grover, P. J. Org. Chem. 1996, 61, 3534.
38. Sheehan, J. C.; Zachau, H. G.; Lawson, W. B. J. Am. Chem. Soc. 1958, 80, 3349.
39. For a library based upon 4-hydroxyproline, see: Goldberg, M.; Smith, L., II; Tamayo, N.; Kiselyov, A. S. Tetrahedron 1999, 55, 13887. For a library based upon amide diols, see: Lee, C. E.; Kick, E. K.; Ellman, J. A. J. Am. Chem. Soc. 1998, 120, 9735.
40. For a library based upon 4-hydroxyproline, see: Goldberg, M.; Smith, L., II; Tamayo, N.; Kiselyov, A. S. Tetrahedron 1999, 55, 13887. For a library based upon amide diols, see: Lee, C. E.; Kick, E. K.; Ellman, J. A. J. Am. Chem. Soc. 1998, 120, 9735.
41. Kim, W.; George, A.; Evans, M.; Conticello, V. P. ChemBioChem 2004, 5, 928.
42. (a) Jenkins, C. L.; Lin, G.; Duo, J.; Rapolu, D.; Guzei, I. A.; Raines, R. T.; Krow, G. R. J. Org. Chem. 2004, 69, 8565.
43. (b) Krow, G. R.; Yuan, J.; Lin, G.; Sonnet, P. E. Org. Lett. 2002, 4, 1259.
44. Krow, G. R.; Yuan, J.; Fang, Y.; Meyer, M. D.; Anderson, D. J.; Campbell, J. E.; Carroll, R. J. Tetrahedron 2000, 56, 9227.
45. (a) Kurita, J.; Iwata, K.; Sakai, H.; Tsuchiya, T. Chem. Pharm. Bull. 1985, 33, 4572.
46. (b) The low yield in the photocyclization step can be attributed to competitive aromatization and/or electrocyclic ring opening of the 1,2-dihydropyridine. Kumagai, T.; Saito, S.; Ehara, T. Tetrahedron Lett. 1991, 32, 6895.
47. Krow, G. R.; Lin, G.; Rapolu, D.; Fang, Y.; Lester, W. S.; Herzon, S. B.; Sonnet, P. E. J. Org. Chem. 2003, 68, 5292.
48. Carlsen, H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. J. Org. Chem. 1981, 46, 3936.
49. Hashimoto, N.; Aoyama, T.; Shioiri, T. Chem. Pharm. Bull. 1981, 5, 1475.
50. (a) Krow, G. R.; Lee, Y. B.; Lester, W. S.; Christian, H.; Shaw, D. A.; Yuan, J. J. Org. Chem. 1998, 63, 8558.
51. (b) Krow, G. R.; Lester, W. S.; Liu, N.; Yuan, J.; Hiller, A.; Duo, J.; Herzon, S. B.; Nguyen, Y.; Cannon, K. J. Org. Chem. 2001, 66, 1811.
52. Boeckman, R. K., Jr.; Potenza, J. C. Tetrahedron Lett. 1985, 26, 1411.
53. Tsuzuki, K.; Nakajima, Y.; Watanabe, T.; Yanagiya, M.; Matsumoto, T. Tetrahedron Lett. 1978, 19, 989.
54. Comins, D. L.; Libby, A. H.; Al-awar, R. S.; Foti, C. J. J. Org. Chem. 1999, 64, 2184.
55. The rearrangement of alcohol 22 might be envisioned as occurring through a series of steps shown in Scheme 5. An alcohol proton catalyzed ring opening could give a β-silyl cation i. A subsequent 1,2-alkyl shift gives a ring-enlarged cation ii. Proton loss generates an allylic silane iii. Desilylation accompanied by bromide elimination gives diene iv and a series of acid-catalyzed proton transfers affords ketone 23.
56. Fleming, I.; Henning, R.; Parker, D. C.; Plaut, H. E.; Sanderson, P. E. J. J. Chem. Soc., Perkin Trans. 1 1995, 317.
57. Anelli, P. L.; Biffi, C.; Montanari, F.; Quici, S. J. Org. Chem. 1987, 52, 2559.